Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
09/2012
09/18/2012CA2424602C Antibody composition-producing cell
09/18/2012CA2369812C Mink-related genes, formation of potassium channels and association with cardiac arrhythmia
09/18/2012CA2279554C Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
09/13/2012WO2012122533A2 Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
09/13/2012WO2012122528A1 Bispecific three-chain antibody-like molecules
09/13/2012WO2012122514A1 Extracellular targeted drug conjugates
09/13/2012WO2012122513A2 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
09/13/2012WO2012122512A1 Recombinant production of mixtures of single chain antibodies
09/13/2012WO2012122484A1 Methods and reagents for creating monoclonal antibodies
09/13/2012WO2012122125A2 Compositions and methods targeting force generation in kinesin
09/13/2012WO2012121775A2 Dual variable domain immunoglobulins and uses thereof
09/13/2012WO2012121740A1 Manufacturing and purification processes of complex proteins found in fraction iv
09/13/2012WO2012121409A1 Method for purifying physiologically active substance using temperature-responsive chromatography carrier
09/13/2012WO2012121172A1 Ice crystallization inhibitor derived from plant seeds
09/13/2012WO2012120518A1 Compositions and methods for diagnosing and treating phenylketonuria (pku)
09/13/2012WO2012120128A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
09/13/2012WO2012120125A1 Humanised anti ctla-4 antibodies
09/13/2012WO2012120124A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/13/2012WO2012120035A1 Anti oligomer antibodies and uses thereof
09/13/2012WO2012119989A2 Methods and antibodies for the diagnosis and treatment of cancer
09/13/2012WO2012095432A3 Tlr3 binding agents
09/13/2012WO2012087962A3 Anti-mesothelin antibodies and immunoconjugates
09/13/2012WO2012078633A8 Methods of inhibiting metastasis from cancer
09/13/2012WO2012072268A3 Anti cd4 antibodies to prevent in particular graft -versus - host - disease (gvhd)
09/13/2012WO2012061904A8 Histone protein ubiquitination as a cancer biomarker
09/13/2012WO2011088120A8 Antibody formulation and therapeutic regimens
09/13/2012US20120233716 Novel fatty acid elongase and uses thereof
09/13/2012US20120232463 De novo synthesis of bacteriochlorins
09/13/2012US20120231504 Multiuse reactors and related methods
09/13/2012US20120231450 Novel pacemaker cell
09/13/2012US20120231094 Hair Shape Susceptibility Gene
09/13/2012US20120231024 Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen as diagnostic and therapeutic tools for prostate cancer
09/13/2012US20120231021 Antibodies specifically binding to the epidermal growth factor receptor
09/13/2012US20120231019 Fibrosis inhibitor
09/13/2012US20120231013 Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
09/13/2012US20120231011 Anti-vegf monoclonal antibody and pharmaceutical composition comprising said antibody
09/13/2012US20120231008 Anti-C5A Binding Moieties with High Blocking Activity
09/13/2012US20120231006 Anti-orai1 antigen binding proteins and uses thereof
09/13/2012US20120231005 Ax1 and ax189 psck9 antagonists and variants
09/13/2012US20120231004 Antibodies
09/13/2012US20120231003 Ox2 Receptor Homologs
09/13/2012US20120231002 Treatment of vasculoproliferative conditions
09/13/2012US20120230999 Bispecific nanobodies as a therapeutic for alzheimer's disease
09/13/2012US20120230998 Ip-10 antibodies and their uses
09/13/2012US20120230996 Compositions And Methods For Macular Degeneration
09/13/2012US20120230995 Polyspecific binding molecules and uses thereof
09/13/2012US20120230992 Vegf-related protein
09/13/2012US20120230990 Humanized antibodies against human il-22ra
09/13/2012US20120230986 Agent and Methods for Reducing Inflammatory Markers
09/13/2012US20120230985 Humanized anti-factor d antibodies and uses thereof
09/13/2012US20120230981 CH2 Domain Template Molecules Derived From Rational Grafting Of Donor Loops Onto CH2 Scaffolds
09/13/2012US20120230980 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
09/13/2012US20120230979 NOGO Receptor Binding Protein
09/13/2012US20120230978 Compositions and methods for modulating circadian synchronization
09/13/2012US20120230962 Gp100-specific t cell receptors and related materials and methods of use
09/13/2012US20120230945 Targeted particles and methods of using the same
09/13/2012US20120230912 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
09/13/2012US20120230911 Tnf-alpha binding proteins
09/13/2012CA2829606A1 Methods and reagents for creating monoclonal antibodies
09/13/2012CA2829128A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/13/2012CA2829110A1 Low fucose cell lines and uses thereof
09/13/2012CA2829037A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
09/13/2012CA2828940A1 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
09/13/2012CA2828528A1 Humanised anti-ctla4 antibodies
09/13/2012CA2828347A1 Bispecific three-chain antibody-like molecules
09/13/2012CA2827759A1 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
09/13/2012CA2821976A1 Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
09/12/2012EP2497831A1 TB vaccination using HCMV-based vaccine vectors
09/12/2012EP2497829A1 Super-agonistic anti-CD-28 antibodies
09/12/2012EP2497783A2 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
09/12/2012EP2497782A1 Anti oligomer antibodies and uses thereof
09/12/2012EP2497779A1 Klebsiella antigens
09/12/2012EP2497498A1 Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
09/12/2012EP2497496A2 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
09/12/2012EP2497491A1 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
09/12/2012EP2497489A1 Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/12/2012EP2497485A1 Compound and method for regulating plasminogen activation and cell migration
09/12/2012EP2496707A1 Engineered anti-tslp antibody
09/12/2012EP2496609A2 Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
09/12/2012EP2496608A2 Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same
09/12/2012EP2496606A2 Treating basal-like genotype cancers
09/12/2012EP2496605A1 Ror1 as therapeutic and diagnostic target
09/12/2012EP2496604A1 Canine anti-cd20 antibodies
09/12/2012EP2496603A1 Glycosylated repeat-motif-molecule conjugates
09/12/2012EP2496602A1 Chimeric anti-ricin antibody
09/12/2012EP2496601A1 Methods and composition for secretion of heterologous polypeptides
09/12/2012EP2496600A1 Methods for affinity maturation-based antibody optimization
09/12/2012EP2496270A1 Zirconium-radiolabeled, cysteine engineered antibody conjugates
09/12/2012EP2496257A1 Treatment of cancer involving mutated kras or braf genes
09/12/2012EP2496256A2 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
09/12/2012EP1360287B1 Methods of modifying eukaryotic cells
09/12/2012CN102667480A Fluoroimmunoasssay method
09/12/2012CN102666589A Antibodies to epha3
09/12/2012CN102666588A Treating basal-like genotype cancers
09/12/2012CN102666587A Methods for treatment of muscular dystrophy
09/12/2012CN102666586A Drug fusions and conjugates with extended half life
09/12/2012CN102666585A Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
09/12/2012CN102666584A Blocking anti-DKK-1 antibodies and their uses
09/12/2012CN102666583A 革兰氏阳性细菌特异性结合化合物 Gram-positive bacteria-specific binding compound
09/12/2012CN102666582A Sequence dependent aggregation
1 ... 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 ... 1494